VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new stake in shares of DaVita Inc. (NYSE:DVA - Free Report) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 15,900 shares of the company's stock, valued at approximately $3,537,000.
Several other hedge funds have also recently made changes to their positions in the stock. California State Teachers Retirement System lifted its position in DaVita by 18,932.5% during the second quarter. California State Teachers Retirement System now owns 8,610,866 shares of the company's stock valued at $1,915,745,000 after purchasing an additional 8,565,623 shares during the period. HB Wealth Management LLC raised its stake in DaVita by 27.0% during the 2nd quarter. HB Wealth Management LLC now owns 2,420 shares of the company's stock valued at $538,000 after buying an additional 515 shares during the last quarter. Compass Financial Management LLC bought a new position in shares of DaVita during the 2nd quarter valued at $72,000. NEOS Investment Management LLC boosted its stake in shares of DaVita by 5.3% in the 2nd quarter. NEOS Investment Management LLC now owns 5,021 shares of the company's stock worth $1,117,000 after buying an additional 253 shares during the last quarter. Finally, Nykredit A S bought a new stake in shares of DaVita in the second quarter worth $1,062,000. 90.12% of the stock is owned by hedge funds and other institutional investors.
Insider Buying and Selling at DaVita
In related news, insider Kathleen Waters sold 15,405 shares of the business's stock in a transaction on Monday, June 15th. The shares were sold at an average price of $208.40, for a total value of $3,210,402.00. Following the sale, the insider owned 109,194 shares in the company, valued at approximately $22,756,029.60. The trade was a 12.36% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Company insiders own 1.90% of the company's stock.
Analyst Upgrades and Downgrades
A number of research analysts have weighed in on the company. Zacks Research downgraded DaVita from a "strong-buy" rating to a "hold" rating in a report on Monday, July 6th. TD Cowen upgraded shares of DaVita from a "hold" rating to a "buy" rating and increased their price objective for the stock from $201.00 to $220.00 in a research note on Friday, August 7th. Oppenheimer set a $220.00 target price on shares of DaVita in a research report on Friday, August 7th. Weiss Ratings raised shares of DaVita from a "hold (c+)" rating to a "buy (b-)" rating in a report on Wednesday, August 5th. Finally, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $265.00 price target on shares of DaVita in a research note on Wednesday, August 5th. Four research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $233.43.
Read Our Latest Report on DaVita
DaVita Trading Up 1.7%
Shares of DVA opened at $183.11 on Thursday. DaVita Inc. has a 12-month low of $101.00 and a 12-month high of $247.49. The business's 50 day moving average is $206.15 and its 200 day moving average is $185.25. The company has a market capitalization of $11.68 billion, a PE ratio of 14.98, a price-to-earnings-growth ratio of 0.47 and a beta of 0.83.
DaVita (NYSE:DVA - Get Free Report) last posted its earnings results on Tuesday, August 4th. The company reported $4.02 earnings per share for the quarter, beating the consensus estimate of $3.88 by $0.14. The company had revenue of $3.55 billion during the quarter, compared to analysts' expectations of $3.50 billion. DaVita had a net margin of 6.05% and a negative return on equity of 217.63%. DaVita's quarterly revenue was up 5.2% on a year-over-year basis. During the same period last year, the company posted $2.95 earnings per share. DaVita has set its FY 2026 guidance at 14.100-15.200 EPS. Equities research analysts predict that DaVita Inc. will post 14.57 earnings per share for the current year.
DaVita Profile
(
Free Report)
DaVita Inc NYSE: DVA is a leading provider of kidney care services, specializing in the management and operation of outpatient dialysis centers for patients with chronic kidney failure and end-stage renal disease. Headquartered in Denver, Colorado, the company offers a comprehensive suite of treatment modalities, including in-center hemodialysis, peritoneal dialysis, and home dialysis therapies. In addition to its core dialysis services, DaVita provides patient education, nutritional counseling, vascular access management and related laboratory services to support kidney health and overall patient well-being.
Since its formation in the mid-1990s through a clinical management services spin-off, DaVita has expanded both organically and through strategic partnerships and acquisitions.
Read More

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider DaVita, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and DaVita wasn't on the list.
While DaVita currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.